Pricing deals announced by #NHSEngland for Perjeta (pertuzumab) & Mavenclad (cladribine) indicate a new approach to the pricing of innovative drugs in the UK. Previously, manufacturers proposed a price to #NICE, which made a..>> click to read more
Patient-centricity: shaping value generation for HTA and market access
With patient-centricity becoming a new paradigm for the pharmaceutical industry, this webinar will examine the role of patient engagement in HTA and market access processes, and how this enhances value generation for drug approvals. Focusing on Europe, we will analyze the different models and guidelines in place.
"Please let your staff who supported us know how appreciative we are of their efforts. From the advisory boards to the GVD development to the modeling efforts and numerous projects, the support and partnership was great. The accomplishment in the UK with NICE is absolutely exceptional."
ISPOR Glasgow is nearly upon us! Join us at booth 404 to discuss your market access challenges
Subscribe now to get the latest updates from PRMA Consulting
Market access update key learnings from ASCO and EHA 2017
In this webinar, we discuss the evolution of value frameworks, the OCM, and incorporating the patient perspective. We also consider the implications for payers of new data on CAR-Ts; key points to think about when planning for market access of a combination; and how payers might handle products approved on the basis of basket trials.
"Just wanted to say great job presenting today. The commercial team increasingly want to be involved in these discussions and your discussion points and delivery were great for the access and broader team. Thanks for making the information practical and insightful. I think the overall response from the team was very positive and the content will ultimately be incredibly helpful for our strategy."
Market access for PD-1 inhibitors: where are we now?
With three products targeting the PD-1 pathway now approved, and other launches expected in 2017, this webinar will take stock of payers’ reactions to the products. Focusing on Europe, we will look at the decisions that have been made to date and discuss these further.